Related Articles
Tumor microenvironment immune types in gastric cancer are associated with mismatch repair however, not HER2 status
Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer
Expression and clinical significance of PD‑1 in hepatocellular carcinoma tissues detected by a novel mouse anti-human PD‑1 monoclonal antibody
Phospho‑STAT1 expression as a potential biomarker for anti‑PD‑1/anti‑PD‑L1 immunotherapy for breast cancer
MicroRNAs aid the assessment of programmed death ligand 1 expression in patients with non‑small cell lung cancer